28 September 2020
Johnson & Johnson (J&J) subsidiary Janssen has reported positive interim data from an ongoing Phase I/IIa clinical trial of a potential Covid-19 vaccine, JNJ-78436735. According to the results, a single dose of the vaccine candidate showed a strong neutralising antibody response in almost all participants aged 18 years and above. The candidate was observed to be generally well-tolerated. J&J added that immune responses were similar across the age groups, including older adults.
Go deeper with GlobalData
Manchester University NHS Foundation Trust in the UK has started dosing Covid-19 patients with severe lung disease in the OSCAR study assessing GlaxoSmithKline (GSK)’s otilimab. The first patient has been enrolled and is being treated at the Manchester Royal Infirmary (MRI). The trial is designed to be conducted at hospitals across the UK.
A Government panel in India has rejected Glenmark’s proposal for a Phase III clinical trial of favipiravir plus dexamethasone to potentially treat Covid-19, as reported by The Print news agency. The panel said that the justification offered for use of the combination treatment in all patients with moderate Covid-19 in the test arm is not adequate.
Novavax has signed a non-exclusive agreement with Endo International subsidiary Par Sterile Products for fill-finish manufacturing services for its Covid-19 vaccine candidate. Par Sterile’s plant in Rochester, Michigan, has started manufacturing the vaccine’s final drug product and initial batches are meant for use in a Phase III trial in the US.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
